Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: A multicentric pilot-evaluation

Annals of Oncology

Volumn 10, Issue 1, 1999, Pages 87-95

  Freyer, G ^e   Dazord, A ^a   Schlumberger, M ^b   Conte Devolx, B ^c   Ligneau, B ^d   Trillet Lenoir, V ^f   Lenoir, G M ^d  

^a Hopital Saint Jean de Dieu   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c TIMONE HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f NONE

Author keywords

Genetic testing; Medullary thyroid carcinoma; Psychometric scores; Psychosocial impact; Quality of life

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FAMILIAL CANCER; FEMALE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; RISK ASSESSMENT; SOCIAL ASPECT; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; CARCINOMA, MEDULLARY; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PILOT PROJECTS; PSYCHOLOGY; QUALITY OF LIFE; THYROID NEOPLASMS;

EID: 0033035199     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008349318728     Document Type: Article

References (41)

1. Annas GJ. Genetic prophecy and genetic privacy. Can we prevent the dream from becoming a nightmare? Am J Public Health 1995; 85: 1196-7.
2. Collins FS. Ethical, legal and social implications of DNA testing for cancer predisposition. Anti Cancer Res 1994; 210-5.
3. Maddox J. New genetics means no new ethics. Nature 1993; 364: 97.
4. Schneider K, Farkas Patenaude A, Garber JE. Testing for cancer genes: Decisions. Nature Med 1995; 1: 302-3.
5. Eng C, Stratton M, Ponder B et al. Familial cancer syndromes. Lancet 1994; 343: 709-13.
6. Evans GR, Blair V, Greenhalgh R et al. The impact of genetic-counseling on risk perception in women with a family history of breast cancer. Br J Cancer 1994; 70: 934-8.
7. Ellman R, Angeli N, Hristian AC et al. Psychiatric morbidity associated with screening for breast cancer. Br J Cancer 1989; 60: 781-4.
8. Healy B. Hearing on the possible uses and misuses of genetic information. Hum Gene Ther 1992; 3: 51-6.
9. Biesecker BB, Boehnke M, Calzone K et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993; 269: 1970-1974.
10. Lynch H, Lynch J, Conway T, Severin M. Psychological aspects of monitoring high risk women for breast cancer. Cancer 1994; 74: 1184-92.
11. Lerman C, Rimer BK, Trock B. Factors associated with repeat adherence to breast cancer screening. Prevent Med 1990; 19: 279-90.
12. Lerman C, Rimer BK, Engstrom PF. Cancer risk notification: Psychological and ethical implications. J Clin Oncol 1991; 9: 1275-82.
13. Lerman C, Schwartz M. Adherence and psychological adjustment among women at high risk for breast cancer. Breast Cancer Res Treat 1993; 28: 145-55.
14. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994; 12: 843-50.
15. Lerman C, Lustbader E, Rimer B et al. Effects of individualized breast cancer risk counseling: A randomized trial. J Natl Cancer Inst 1995; 87: 286-92.
16. Kash K, Holland JC, Halper MS, Miller DG. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst 1992; 84.
17. Ishida T, Sugimachi K, Yano T. Psychosocial distress and breast cancer screening among women at high risk: Where are we? J Natl Cancer Inst 1992; 84: 1756-7.
18. Grosfeld FJM, Lips CJM, Beemer FA. Psychosocial consequences of DNA analysis for MEN type 2. Oncology 1996; 10: 141-6.
19. Halowell N, Murton F, Statham H et al. Women's need for information before attending genetic counselling for familial breast/ovarian cancer: A questionnaire interview and observational study. BMJ 1997; 314: 281-4.
20. Schuffenecker I, Billaud M, Calender A et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994; 3: 1939-43.
21. Zigmond S, Snaith RP. The hospital anxiety and depression scale (HADS). Acta Psychiatr Scand 1983; 67: 361-70.
22. Razavi D, Delvaux N, Farvacques C, Robayes E. Screening for adjustment disorders and major depressive disorders in cancer in patients. Br J Psychiat 1990; 156: 79-83.
23. Dazord A, Mercier C, Magnificat S, Nicolas J. French subjective quality of life questionnaire: Main results. Eur Rev Appl Psychol 1995; 4: 271-9.
24. Dazord A. Quality of life assessment in medicine. Presentation of a new instrument (SQLP: subjective quality of life profile) and first results. Eur Respirat Rev 1995; 5: 66-71.
25. Dazord A, Mino A, Page D, Broers B. Patients on methadone maintenance in Geneva. Eur Psychiat 1998; 13: 235-41.
26. Nunally JC. Psychometric Theory. second ed. New-York: Mac Graw-Hill Book 1978.
27. Lynch H, Watson P. Genetic counselling and hereditary breast ovarian cancer. Lancet 1992; 339: 1181.
28. Lynch H, Walson P, Conway T et al. DNA screening for breast-ovarian cancer susceptibility based on linked markers. Arch Intern Med 1993; 153: 1979-87.
29. King MC, Rowell S, Love S. Inherited breast and ovarian cancer: What are the risks? What are the choices? JAMA 1993; 15: 1975-80.
30. National advisory council for human genome research. Statement on use of DNA testing for presymtomatic identification of cancer risk. JAMA 1994; 271: 785.
31. Parker DE. Bioethics for human geneticists: Models for reasoning and methods for teaching. Am J Hum genet 1994; 54: 137-47.
32. Clauss F, Schwatrz PE. Familial ovarian cancer. Update and clinical applications. Cancer 1995; 76: 1998-2003.
33. Michie S, Mac Donald V, Marteau T. Understanding responses to predictive genetic testing: A grounded theory approach. Psychol Health 1997; 14: 327-34.
34. Cleiren M, Oskam W, Lips C et al. Living with a hereditary form of cancer: Experiences and needs of MEN2 patients and their families. Henry Ford Med Hosp J 1989; 37: 164-6.
35. Eales RA, Stratton MR, Goldgar DE, Easton DF. The genetics of familial breast cancer and their clinical implications. Eur J Cancer 1994; 30A: 1383-90.
36. Ford D, Eastern DF, Bishop T et al. Risks of cancer in BRCA1 mutation carriers. Lancet 1994; 343: 692-5.
37. Chaliki H, Loader S, Levenkron JC et al. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 1995; 85: 1133-5.
38. Marra G, Boland CR. Hereditary non polyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995; 87: 1114-25.
39. Voelker R. The genetic revolution: Despite perfection of elegant techniques, ethical answers still elusive. JAMA 1993; 270: 2273-4.
40. Wardle FJ, Collins W, Pernet AL et al. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst 1993; 85: 653-7.
41. Redelmeier DA, Rozin P, Kahneman D. Understanding patient's decisions. Cognitive and emotional perspectives. JAMA 1993; 270: 72-6.